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Abstract
Background: Tumor suppressor gene TUSC2/FUS1 (TUSC2) is frequently inactivated early in lung cancer development. TUSC2
mediates apoptosis in cancer cells but not normal cells by upregulation of the intrinsic apoptotic pathway. No drug
strategies currently exist targeting loss-of–function genetic abnormalities. We report the first in-human systemic gene
therapy clinical trial of tumor suppressor gene TUSC2.
Methods: Patients with recurrent and/or metastatic lung cancer previously treated with platinum-based chemotherapy
were treated with escalating doses of intravenous N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride
(DOTAP):cholesterol nanoparticles encapsulating a TUSC2 expression plasmid (DOTAP:chol-TUSC2) every 3 weeks.
Results: Thirty-one patients were treated at 6 dose levels (range 0.01 to 0.09 milligrams per kilogram). The MTD was
determined to be 0.06 mg/kg. Five patients achieved stable disease (2.6–10.8 months, including 2 minor responses). One
patient had a metabolic response on positron emission tomography (PET) imaging. RT-PCR analysis detected TUSC2 plasmid
expression in 7 of 8 post-treatment tumor specimens but not in pretreatment specimens and peripheral blood lymphocyte
controls. Proximity ligation assay, performed on paired biopsies from 3 patients, demonstrated low background TUSC2
protein staining in pretreatment tissues compared with intense (10–25 fold increase) TUSC2 protein staining in post-
treatment tissues. RT-PCR gene expression profiling analysis of apoptotic pathway genes in two patients with high post-
treatment levels of TUSC2 mRNA and protein showed significant post-treatment changes in the intrinsic apoptotic pathway.
Twenty-nine genes of the 82 tested in the apoptosis array were identified by Igenuity Pathway Analysis to be significantly
altered post-treatment in both patients (Pearson correlation coefficient 0.519; p,0.01).
Conclusions: DOTAP:chol-TUSC2 can be safely administered intravenously in lung cancer patients and results in uptake of
the gene by human primary and metastatic tumors, transgene and gene product expression, specific alterations in TUSC2-
regulated pathways, and anti-tumor effects (to our knowledge for the first time for systemic DOTAP:cholesterol nanoparticle
gene therapy).
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Introduction
The focus of cancer therapy has shifted from the tissue to the
genetic level. [1] Mutations in two major classes of genes,
oncogenes and tumor suppressor genes (TSGs), play central roles
in the oncogenic process. TSGs appear to require homozygous
deletion or mutation for inactivation, [2] and restoration of TSG
expression is feasible in human tumors. [3] Intratumoral injection
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34833of retroviral or adenoviral vectors expressing the wildtype TSG
p53 have been performed in patients with locally advanced non-
small cell lung cancer (NSCLC) and head and neck cancer. [4,5,6]
These studies showed that viral vectors expressing the TSG p53
can be safely injected into tumors repetitively and can mediate
tumor regression. However, because of the systemic immune
response, current viral vectors are limited to intratumoral
administration or single intravenous doses, which may not be
optimal treatment for tumor metastases, the primary cause of
cancer-related death. Thus development of vectors for intrave-
nous, systemic TSG replacement would represent a significant
advance. Homozygous deletions in the 3p21.3 region in lung
cancer cell lines and primary lung tumors have led to the
identification of multiple genes with tumor suppressor activity. [7]
Among these genes, TUSC2, consistently demonstrates the highest
level of tumor suppressor activity. [8] Here we report the first-in-
human, dose-escalation clinical trial of intravenous DOTAP:cho-
lesterol(DC)-TUSC2 in patients with incurable, recurrent and/or
metastatic lung cancer previously treated with platinum-based
chemotherapy. The primary objectives of the clinical trial were to
assess the toxicity of DOTAP:chol-TUSC2 administered intrave-
nously and to determine the maximal tolerated dose and
recommended phase II dose of DOTAP:chol-TUSC2 administered
intravenously. Secondary objectives were to assess the expression
of TUSC2 following intravenous delivery of DOTAP:chol-TUSC2
in tumor biopsies and assess any anti-cancer activity for
DOTAP:chol-TUSC2. This is the first, to our knowledge, systemic
gene therapy clinical trial that uses an intravenous nanoparticle-
delivery system for delivering a tumor suppressor gene expression
plasmid (Phase I Study of IV DOTAP: Cholesterol-Fus1 in Non-
Small-Cell Lung Cancer.
Methods
Please see Information S1 for detailed methods.
Trial Protocol
The protocol for this trial is available as Protocol S1.
DC nanoparticle preparation
DOTAP GMP grade was purchased from Avanti Polar Lipids,
Inc. (Alabaster, AL) and cholesterol GMP grade was purchased
from Sigma-Aldrich (St. Louis, MO). A ratio of 20 mM
DOTAP:18 mM cholesterol was used for preparation of the
nanoparticles. The reagents were mixed and the dry lipids
dissolved in purified GMP grade chloroform. A Buchi rotary
evaporator was used to form a dry lipid film. Further drying was
performed under a vacuum in a Labconco Freeze dry system. The
film was resuspended in sterile 5% dextrose in water. After
sonication the following day under aseptic conditions the lipids are
sequentially extruded through a series of sterile Whatman filters
from 1 um to 0.1 um in pore size.
Plasmid production
The pLJ143-KGB2-TUSC2 plasmid vector was produced under
GMP conditions at the Baylor College of Medicine Center for Cell
and Gene Therapy (Houston, TX) and the Beckman Research
Institute of the City of Hope (Duarte, CA). The toxicity profiles
did not differ for the two production lots (Table S1 – Dose-
escalation scheme). Both lots had similar quality control
specifications (Table S2 – Plasmid quality control specifications).
The plasmid structure, restriction enzyme map, and sequence are
shown in Figures S1 (Structure and restriction enzyme map of
pLJ143/KGB2/FUS1 plasmid vector) and Figure S2 (Positions
and direction of DNA sequencing primers for pLJ143/KGB2/
FUS1 vector) and Table S3(DNA sequence of pLJ143/KGB2/
FUS1).
DC-TUSC2 nanoparticle preparation
The diluted plasmid DNA and diluted nanoparticle stock were
mixed in equal volumes to a final concentration of 4 mM DOTAP
and 0.5 mg/ml of DNA. Prior to treatment the assigned dose was
diluted in 100 ml 5% dextrose in water (D5W). A negative gram
stain was required prior to treatment.
Study Design
Eligible patients were required to have histologically document-
ed NSCLC or SCLC not curable by standard therapies and
previously treated with platinum-based chemotherapy. Cycles
consisted of a single intravenous infusion every 21 days. The
presence of viable cancer cells in the biopsied lesion was confirmed
in all cases by histopathological examination. Mandatory biopsies
for gene expression analysis were explicitly precluded by
regulatory committees at the local and federal level. Tumor
response assessed by computed tomography (CT) scans was
determined in accordance with standard World Health Organi-
zation (WHO) criteria. [9] This study was approved by the
University of Texas MD Anderson Institutional Review Board, the
NIH Recombinant DNA Advisory Committee, and the FDA. All
patients provided written informed consent prior to entry into the
study.
Expression of TUSC2 plasmid in human tumors
Tissue was obtained by 20 gauge needle core biopsy using CT
guidance. All specimens were blinded for patient identity, clinical
information and specimen timing (pre- vs post-treatment) during
all studies. Ectopic expression of the TUSC2 gene in patient biopsy
samples was analyzed using a TaqMan based quantitative real
time reverse transcriptase-polymerase chain reaction (RT-PCR)
(Applied Biosystems, Foster City, CA).
In situ Proximity Ligation Assay (PLA) for TUSC2 protein in
tumor biopsies
The rabbit anti-TUSC2 polyclonal antibody used for immuno-
histochemical staining was raised against a synthetic oligopeptide
derived from the TUSC2 NH2-terminal amino acid sequence
(NH2-GASGSKARGLWPFAAC). The specificity of this antibody
for TUSC2 was previously characterized. [10,11] Duolink kits
from Olink Biosciences (Uppsala, Sweden) were used to analyze
changes in TUSC2 protein expression in pre- and post-treatment
tumor biopsies.
Statistical Analysis
The initial starting dose (0.02 mg/kg) was selected based on
toxicology studies in non-human primates. This dose was one
tenth the dose which resulted in no deaths in non-human primates.
After the sixth patient was enrolled, the starting dose was amended
to 0.01 mg/kg. Dose escalation was based on a continuous
reassessment method (CRM) which allows the MTD to be
periodically re-estimated (see Protocol S1 for complete description)
[12] The MTD was defined as the highest dose level in which no
more than 10% of patients develop dose-limiting toxicity (DLT),
defined as grade 3 non-hematologic or hematologic toxicity during
cycle 1 judged by the investigator to be related to DOTAP:chol-
TUSC2. Patients entered at a given dose level were not eligible for
dose escalation or dose reduction. A cohort of 3 patients was
treated at each dose level. After treating 3 patients at a given dose
TUSC2(FUS1)
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used to compute the posterior probability of toxicity. Only toxicity
during cycle 1 was used to determine the next dose level. If no
DOTAP:chol-TUSC2-related toxicities were observed in any prior
patient, the subsequent dose level was increased by 100%. If only
grade 1 or 2 toxicities were observed, the subsequent dose level was
increased by 50%. If any DLT was observed, the CRM could lead
to either escalation or reduction of dose levels. If DLT occurred and
the CRM resulted in a dose escalation, the subsequent dose level
was increased by 25%. The computer program crm.exe was used
(http://odin.mdacc.tmc.edu/anonftp/). Toxicity was graded ac-
cording to the National Cancer Institute Common Toxicity
Criteria, version 2.0. Tumor status was assessed at baseline and
after every two cycles of therapy with computed tomography (CT)
scans and/or positron emission tomography (PET)/CT scans.
Expression of major genes in apoptosis signaling pathways in tumor
fine needle biopsies from human lung cancer patients before and
after systemic treatment with DOTAP:chol-TUSC2 nanoparticles
were quantified using a qRT Profiler Apoptosis PCR Array with
RT Nano PreAmp-mediated cDNA synthesis (SA Biosciences,
Frederick, MD). The quantitative apoptotic gene expression data
were analyzed through the use of Ingenuity Pathway Analysis
(Ingenuity Systems, Inc. Redwood City CA (www.ingenuity.com)
(IPA)). For the network and canonical pathway analysis, the
quantitative PCR data set containing gene identifiers and
corresponding expression fold change values was uploaded into
the application. Each identifier was mapped to its corresponding
object in Ingenuity’s Knowledge Base (IKB). An expression fold
change (posttreatment/pretreatment) cutoff of 3 was set to identify
molecules whose expression was significantly differentially regulat-
ed. These molecules, called Network Eligible molecules, were
overlaid onto a global molecular network developed from
information contained in IKB. Networks of Network Eligible
Molecules were then algorithmically generated based on their direct
or indirect connectivity. The Network molecules associated with
biological functions in IKB were considered for analysis. Right-
Figure 1. Consort style flowchart of participants through the study.
doi:10.1371/journal.pone.0034833.g001
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the probability that each biological function assigned to a given
network is due to chance alone. Molecules from the data set that
met the above gene expression fold changes cutoff were also
considered for the canonical pathway analysis. The significance of
the association between the data set and the canonical pathway was
measured by a ratio of the total number of molecules from the data
set that map to the pathway to the total number of molecules that
map to the canonical pathway in IKB. A Fisher’s exact test was used
to calculate a p-value determining the probability that the
association between the genes in the dataset and the canonical
pathway is explained by chance alone. A binomial sampling model
using an exact test of proportions, was used to test the null
hypothesis that coordinated gene expression for both patients
occurred by chance using the R statistical package (http://cran.r-
project.org/). Comparisons in the PLA were are by two-tailed
unpaired Student’st-testassuming equalvariancesas determined by
F test using GraphPad Prism software (GraphPad Software, Inc., La
Jolla, CA). Median survival was determined by the Kaplan Meier
method using SPSS statistical software version 15 (IBM, Armonk,
NY).
Results
One hundred and twenty seven patients were assessed for
eligibility, 31 patients were enrolled between May 5, 2003 and
January 6, 2010 and all patients in the study were treated at a
single institution (Figure 1). Patient characteristics are described in
Table 1. The IRB did not permit mandatory tumor biopsies;
however, eight patients consented to pre and post-treatment tumor
biopsies.
Toxicity and Maximum Tolerated Dose (MTD)
Determination
A total of 74 cycles of DC-TUSC2 were administered, with a
median of 2 cycles (range, 1 to 12 cycles) per patient. Patients were
treated at 6 dose levels ranging from 0.01 to 0.09 mg/kg. The dose
escalation scheme, including number of patients, number of cycles,
and toxicities judged to be related to DC-TUSC2 are listed in
Table 2. Twenty-three patients received two or more doses. The
first patient in cohort 1 (receiving 0.02 mg/kg) developed grade 2
fever within 3 hours of the DC-TUSC2 infusion. The subsequent
patients in cohorts 1 and 2 were given dexamethasone and
diphenhydramine prior to receiving DC-TUSC2, and no grade 1
or higher toxicites were observed. However, after discussions with
the FDA, it was mandated that the next patient cohort receive
DC-TUSC2 at a lower dose level of 0.01 mg/kg without
dexamethasone or diphenhydramine premedication. All three
patients developed grade 2 or 3 fever and one patient developed
grade 3 hypotension. The FDA then allowed the protocol to be
amended to require dexamethasone and diphenhydramine
premedications beginning with the next cohort (patient 10),
starting at a dose level of 0.01 mg/kg. Due to this amendment, it
was decided not to use the toxicity data from the first nine patients
for MTD determination, and a subgroup of 21 patients enrolled
between September 28, 2006 and October 29, 2009 were used to
determine the final MTD. The only subsequent dose limiting
toxicities (DLT) observed were grade 3 reversible hypophospha-
temia in two patients with one at 0.06 mg/kg and another at
0.09 mg/kg. In both cases the patients had either grade 1 or 2
fevers and the hypophosphatemia was an incidental laboratory
finding. The MTD was determined to be 0.06 mg/kg. As listed in
Table 2, grade 2 toxicities included myalgias, hypophosphatemia,
fever, nausea, and transaminase elevation. Antibodies to single and
double stranded DNA were not detected 14 months after
completion of 12 cycles of therapy in patient 26. At the time of
entry into the study all patients had tumor progression despite
multiple systemic therapies and had growing tumor(s).
Response and survival
Twenty-three patients received two or more doses (Table 2).
Five patients achieved stable disease which had a duration of 2.6 to
10.8 months (median 5.0, 95%CI 2.0–7.6) until tumor progres-
sion, while all other patients continued to have tumor progression.
Two patients had reductions in primary tumor size of 14% and
26%. One patient with stable disease (patient 26) had evidence of a
metabolic response on positron emission tomography (PET)
imaging and received 12 cycles of therapy. The response was
documented with PET scans performed after the second, fourth
(Figure 2), and sixth doses, all showing decreased metabolic
activity with no changes in size or number of metastases by CT
imaging. This patient remains alive on subsequent therapy 14
months after the final treatment with DC-TUSC2. Median survival
for all patients was 8.3 months (95% CI 6.0–10.5 months) and
mean survival time was 13.2 months (95%CI 8.9–17.5 months)
with a range of 2 to 21+ months. Two of the five patients with
stable disease were in the group which had tumor biopsies. Both
patients (Patient 1 with stable disease for six cycles of treatment
and Patient 26 as described above) had evidence of transgene
Table 1. Baseline Characteristics of Patients.
Characteristic No. of Patients (%) (n=31)
Median age, years (range) 60 (43–76)
Sex
Male 16 (52%)
Female 15 (48%)
ECOG performance status
0 4 (13%)
1 27 (87%)
Histology
Adenocarcinoma 11 (35%)
Bronchoalveolar carcinoma 1 (3%)
Squamous cell carcinoma 3 (10%)
Non-small cell carcinoma, NOS 11 (36%)
Small cell carcinoma 5 (16%)
Prior therapy
Chemotherapy 31 (100%)
Radiotherapy 14 (45%)
Surgery 11 (35%)
Prior chemotherapy regimens
1 9 (29%)
2 9 (29%)
.2 13 (42%)
Number of doses received
1 8 (26%)
2 19 (61%)
$3 4 (13%)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; NOS, not otherwise
specified.
doi:10.1371/journal.pone.0034833.t001
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TUSC2 protein expression which was shown to be increased in
the post-treatment biopsy (Fig. 3).
TUSC2 mRNA Expression Detected by RT-PCR
TUSC2 transgene RNA expression by RT-PCR was not
detected in pre-treatment biopsies (Table 3). Five of six post-
treatment biopsies showed expression of the TUSC2 transgene. In
a seventh patient (Patient No. 31), TUSC2 mRNA was detected
by RT-PCR transgene specific primers included in the qRT
Profiler Apoptosis PCR Array and was detected only in the post-
treatment sample (see below). Expression was not detected in pre-
and post-treatment peripheral blood lymphocytes collected at the
time of the biopsies.
Protein Expression Detected by Proximity Ligation Assay
(PLA)
For three patients sufficient tissue was obtained for determina-
tion of TUSC2 protein expression by proximity ligation assay
(PLA). Anti-TUSC2 antibody was used to detect TUSC2 protein
expression in pre- and post-treatment lung tumor biopsies from
patients 13, 26, and 31 (Figure 3). The post-treatment biopsies
showed intense staining (10 to 25-fold pre-treatment levels) for
TUSC2 protein with very low levels of TUSC2 protein detected
on the paired pre-treatment biopsies. A non-specific control
antibody showed only background staining. Pre-incubation of the
TUSC2 antibody with the specific TUSC2 peptide used to
immunize for antibody production, but not a non-specific peptide,
was able to significantly reduce TUSC2 fluorescence in the post-
treatment biopsies.
Changes in the Apoptosis Pathway Following TUSC2
Treatment
Significant differences in gene expression were detected by an
apoptosis multiplex array assay between pre and post-treatment
biopsies from patients 13 and 31. Post-treatment biopsies from
both patients showed increased levels of vector specific TUSC2
mRNA not present in the pre-treatment biopsies. Twenty-nine
genes of the 82 tested in the apoptosis array were identified by
Igenuity Pathway Analysis (IPA, Ingenuity Systems, Inc. Redwood
City, CA) to be significantly altered post-treatment in both
patients. This subset of genes in the array encompasses the
Table 2. Dose-Escalation Scheme, Toxicities, and Tumor Response.
Cohort No. Dose level (mg/kg) No. of Patients No. of cycles No. patients with DLT
Grade 2 toxicity (No.
patients)
Tumor Response
(No. of patients)
1 0.02 3 9 0 Fever (1) SD (1)
2 0.03 3 6 0 0 SD (1)
3
1 0.01 3 4 2; G3 fever (n=2), G3
hypotension (n=1)
Fever (1)
4* 0.01 3 9 0 0 SD (1)
2
5* 0.02 3 6 0 0
6* 0.04 3 6 0 0
7* 0.06 3 6 0 ALT (1), neuropathy (n=1) SD(1)
3
8* 0.09 3 5 1; G3 hypophosphatemia Fever (1)
9* 0.06 3 16 0 Hypophosphatemia (1), nausea
(1), myalgia (1)
SD(1)
4
10* 0.06 3 5 1; G3 hypophosphatemia Fever (1), myalgia (1),
hypophosphatemia (1),
11 0.06 1 2 0 0
Abbreviations: G3, grade 3; ALT, alanine aminotransferase elevation; SD, stable disease.
1This cohort did not receive dexamethasone or diphenhydramine premedications.
2reduction in primary tumor size of 14%.
3reduction in primary tumor size of 26%.
4metabolic response (Figure 3).
*Cohorts used to determine maximum tolerated dose (MTD).
doi:10.1371/journal.pone.0034833.t002
Figure 2. DC-TUSC2 metabolic tumor response in a metastatic
lung cancer patient. The patient is a 54 year old female with a large
cell neuroendocrine carcinoma. She had received six prior chemother-
apy regimens. Prior to entry in the protocol, two hepatic metastases
were progressing on gemcitabine. The patient also had a metastasis in
the head of the pancreas and a peripancreatic lymph node (arrows). A.
Pretreatment PET scan. The dose of Fluorodeoxyglucose(18F) was
8.8mCi B. Post-treatment PET scan performed 20 days following the
fourth dose of DC-TUSC2. The dose of Fluorodeoxyglucose(18F) was
9.0mCi. All scans were performed within a 60 to 90 minute window
after injection.
doi:10.1371/journal.pone.0034833.g002
TUSC2(FUS1)
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e34833Figure 3. In situ Proximity Ligation Assay (PLA) for TUSC2 protein in tumor biopsies (A). A synthetic oligopeptide (GASGSKARGLWPFA-
SAA) derived from the N-terminal amino-acid sequence of the TUSC2 protein was used to develop the anti-TUSC2 polyclonal antibody in rabbits used
in this study. Red denotes TUSC2 positivity. DAPI nuclear staining is blue. All panels represent overlays of TUSC2 antibody and DAPI staining. Detailed
methods are provided in the Information S1. Pre- and post-treatment biopsies from patients 13, 26, and 31 were tested. Magnification is X40. Panels:
(1) anti-TUSC2 antibody; (2) anti-TUSC2 antibody pre-absorbed with non-specific control peptide (NSP); (3) anti-TUSC2 antibody pre-absorbed with
TUSC2 peptide (FP); (4) non-specific control antibody; (5) hematoxylin and eosin. Quantitation of PLA signals for pre- and post-treatment samples
from patients 13, 26, and 31 (B). The anti-TUSC2 antibody was tested under the conditions described in A). The upper panels show PLA signals from
the respective patient biopsies as detected by the anti-TUSC2 antibody with 4006magnification. The lower panel presents quantitative comparisons
of six independent fields from each biopsy treated under the specified conditions. TUSC2 expression was significantly increased in post-treatment
TUSC2(FUS1)
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two patients were highly positively correlated with respect to
magnitude and direction of change (Pearson correlation coefficient
0.519; p,0.01) The changes in gene expression and canonical
apoptosis pathways following DC-TUSC2 treatment are shown in
Figures S3A and S3B.
Discussion
Loss of heterozygosity in the 3p region is frequently observed in
NSCLC. [13] Genes in the 3p21.3 region are associated with cell
differentiation, cell proliferation, cell cycle kinetics, signal
transduction, ion exchange and transportation, apoptosis, and cell
death. [14] These biological activities are directly or indirectly
associated with the tumor suppression observed when several
3p21.3 genes (including TUSC2) are re-activated in 3p-deficient
tumor cells. Forced expression of wt-TUSC2 in 3p21.3-deficient
NSCLC cells significantly suppressed tumor cell growth by
inducing apoptosis and altering cell cycle kinetics in vitro and in
vivo, thus providing a strong rationale for gene replacement of
TUSC2 in lung cancer as a therapeutic strategy. [8] While point
mutations are rare in the genes at the 3p21.3 locus, [14] there
appear to be regulatory mechanisms that can result in further
reduction of TUSC2 protein expression in the presence of a single
functioning allele. Myristoylation stabilizes the TUSC2 protein
and is required for TUSC2-mediated tumor suppressing activity.
TUSC2 myristoylation is frequently absent in tumors. When
combined with 3p21.3 loss of heterozygosity, loss of myristoylation
results in the absence of functional TUSC2 in cancer cells. [15]
Noncoding RNAs may also regulate expression of TUSC2. [16]
Nanoparticles have been reported to deliver drugs and siRNA
to tumors in humans. [17,18] The current report is the first to
document restoration of tumor suppressor gene function in
primary and metastatic cancers following intravenous gene
delivery as shown by mRNA and protein expression, alterations
in the targeted intrinsic apoptotic pathway, and effects on tumor
growth and metabolic activity. A major limitation of some lipid
nanoparticle gene delivery formulations is instability in vivo,
possibly due in part to interactions with serum proteins. [19]
Templeton and coworkers first showed that the DC formulation
was a more efficient gene delivery system compared to other lipid
formulations. [20] Uptake by the liver was markedly reduced
compared to other lipid formulations and distribution to organs
other than the liver and spleen was increased, with the lung
showing the highest level of gene expression. The DC formulation
prevents binding of proteins to lipid, thus reducing clearance by
the reticuloendothelial system. [21,22] Cationic lipids are a
preferred nanoparticle component for nucleic acid delivery, due
to the high efficiency of nucleic acid transfer associated with these
lipid formulations. Adding neutral lipids to the cationic lipids
increases nanoparticle rigidity and stability. [23] The DC lipoplex
formulation was selected for our study because it achieves a
balance of low toxicity and efficient nucleic acid transfer in vivo.
[20] Due in part to enhanced endocytosis by tumor cells, [24]
uptake of these nanoparticles into tumor cells is 10-fold greater
than into normal cells, thus imparting a passive targeting property
without the need to attach ligands. Using disseminated human
cancer cells in mouse xenograft lung metastases, we showed the
ability of systemic administration of genes via this DC nanoparticle
vector to efficiently deliver therapeutic tumor suppressor genes, to
suppress metastasis growth and to prolong survival. [15,25,26] An
optimized plasmid was developed by using a high-copy number
pMB1 plasmid replication origin element, incorporating a mini-
CMV promoter (not tumor selective), and removing unnecessary
plasmid backbone sequences to keep the plasmid size to a
minimum. We also incorporated E1 enhancer elements with the
mini-CMV promoter since investigators using recombinant
adenoviral vectors have previously noted increased expression of
samples compared to pretreatment samples. TUSC2 expression was not significantly altered by anti-TUSC2 antibody pre-absorption with non-specific
control peptide (NSP), but was significantly decreased by pre-absorption with TUSC2 peptide (FP). * p,0.05 compared to corresponding
pretreatment sample; & p,0.05 compared to post-treatment samples unabsorbed or pre-absorbed with NSP. All comparisons are by two-tailed
unpaired Student’s t-test assuming equal variances as determined by F test.
doi:10.1371/journal.pone.0034833.g003
Table 3. Real Time RT-PCR detection of TUSC2 gene expression in patients receiving DC-TUSC2.
Patient
Number Dose (mg/kg) Site of Tumor Biopsy Treatment
Tumor TUSC2 Gene
Expression (pg/ug tissue)
Tumor TUSC2 Copy
Number (copies/ug
tissue)
Lymphocyte TUSC2
Gene Expression (pg/
ul)
1 0.02 Lung Pre-treatment 0 0 NA
1
1 0.02 Lung Post-treatment 2.0610
2562.20610
210 4.44 NA
7 0.01 Lung Pre-treatment 0 0 NA
7 0.01 Lung Post-treatment 3.6610
2669.1610
27 0.89 NA
13 0.02 Lung Pretreatment 0 0 NA
13 0.02 Lung Post-treatment 3.0610
2561.71610
28 6.22 NA
20 0.06 Liver Pre-treatment 0 0 0
20 0.06 Liver Post-treatment 0 0 0
24 0.09 Subcutaneous nodule Pre-treatment 0 0 0
24 0.09 Subcutaneous nodule Post-treatment 8.0610
2662.33610
28 1.90 0
25 0.06 Lung Pre-treatment 0 0 0
25 0.06 Lung Post-treatment 4.0610
2561.66610
29 8.76 0
1Specimens not available.
doi:10.1371/journal.pone.0034833.t003
TUSC2(FUS1)
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placed under the influence of an E1 enhancer. [27,28] The E1
enhancer was derived from the adenovirus serotype 5 E1A
transcriptional control region containing repeated core sequences.
The E1 enhancer is located between 2141 and 2305 relative to
the E1A cap site at +1. It functions as an enhancer in cis for
enhancing the rate of transcription and steady-state levels of E1A
mRNAs in virus infected cells. [29]
Posttreatment tumor biopsies 24 hours after intravenous gene
therapy administration showed TUSC2 mRNA expression in 7 of
the 8 assessable patients and showed elevated levels of protein
expression in all 3 patients tested.. Although the number of
biopsies was limited due to regulatory constraints, the consistent
results across test platforms and high degree of statistical
significance suggest these observations are reliable. When mRNA
was detectable, the lowest level was seen at the lowest plasmid
dose. One patient at a higher dose did not have detectable mRNA
at the time point measured, possibly due to endogenous tumor
resistance to DC nanoparticle uptake, which we have observed in
some lung cancer cell lines (Meng, J., Ji, L., and Roth, J.,
unpublished observations). Interestingly, the patient who had the
metabolic response had a lung carcinoma with neuroendocrine
features which expressed very low levels of TUSC2 protein.
Prudkin and coworkers observed the lowest levels of TUSC2 in
small cell carcinomas(SCLC), which are also neuroendocrine in
origin. [11] They also observed loss or reduction of TUSC2
protein in 82% of non-small cell lung cancers (NSCLC). We
detected very low levels of TUSC2 protein in pretreatment
biopsies from both responding and non-responding patients. This
observation and the overall high incidence of TUSC2 loss in lung
cancer suggest that loss of TUSC2 protein expression alone may
not be a predictive biomarker for TUSC2 gene therapy.
In this clinical trial, therapy cycles were administered at three
week intervals in order to provide adequate observation time for
toxicity. Previous pharmacokinetic studies in mice showed
circulation in the blood for up to seven days and a t1/2 of nine
to twelve hours (Barnhart K, et al. Systemic apoptotic gene therapy
for pancreatic cancer: multi- dose toxicity study of the BikDD
nanoparticle. In: ASGCT 13th Annual Meeting. Washington, DC;
2010). Alternative schedules for drug administration warrant
testing. Using the dose-schedule tested, this tumor suppressor gene
therapy was well-tolerated with minimal toxicity. Toxicities may
be related to non-specific effects of DC-mediated DNA delivery or
off-target effects of gene expression in normal tissues. However,
the empty DC particle does not cause toxicity in animals, and
uptake of the gene by normal cells in culture does not cause
changes in growth characteristics. [8] [30,31,32] The low level of
side effects after repeated DC administrations is very encouraging
suggesting that DC-TUSC2 may be combined with small molecule
targeted drugs at an effective dose.
We observed major changes in gene expression in the intrinsic
pro-apoptotic pathway in the tumor following DC-TUSC2
treatment. Several lines of evidence suggest this is related to
expression of TUSC2 in the tumor. Preclinical studies in human
lung cancer cell lines identified the intrinsic apoptosis pathway as a
mediator of cell death following forced expression of TUSC2.
[33,34] DC complexed with control plasmid DNA did not induce
apoptosis in lung cancer cells in preclinical studies. Finally, pre-
and post-treatment peripheral blood mononuclear cell intracellu-
lar and plasma cytokine levels for cytokines shown to be induced
by lipid-DNA complexes in mouse studies (IL-1beta, IL-6, IL-8,
IFNgamma, and TNFalpha) were not elevated in patients post-
treatment, most likely because of the peri-treatment immunosup-
pressive regimen, and thus did not contribute to a non-specific
immune response (data not shown). The lack of any significant
toxicity also strongly mitigates against such a mechanism. In
conclusion, we observed for the first time that a functioning TSG
can be delivered intravenously to human cancer cells using a
nanoparticle vector, express mRNA and protein in cancer cells in
the primary tumor and distant metastatic sites, alter relevant
pathways in the cancer cell, and mediate anti-tumor activity.
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